Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.
This purpose of this study is to determine the efficacy of humanized CD19 CAR T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
All biological processes operate under biochemical constraints. The Bailis Lab aims to understand how metabolism controls the development and functional differentiation of the hematopoietic system by setting the biochemical potential of cells and tissues, using in vitro and in vivo CRISPR screening in primary immune cells.
